Pages that link to "Q46014614"

The following pages link to Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. (Q46014614):

Displaying 23 items.

• Pituitary somatostatin receptor signaling (Q24631604) (← links)
• Acromegaly pathogenesis and treatment (Q24647360) (← links)
• Pasireotide: a novel treatment for patients with acromegaly (Q26774437) (← links)
• Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly (Q35228807) (← links)
• Genetic regulation of bone metabolism in the chicken: similarities and differences to Mammalian systems (Q35646074) (← links)
• Molecular targets in pituitary tumours (Q35730308) (← links)
• Somatostatin-dopamine ligands in the treatment of pituitary adenomas. (Q37225446) (← links)
• Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop (Q37244709) (← links)
• Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution (Q37598533) (← links)
• Medical therapy of acromegaly: efficacy and safety of somatostatin analogues (Q37620337) (← links)
• Pasireotide for the treatment of Cushing's disease (Q37763714) (← links)
• Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. (Q37851164) (← links)
• Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. (Q38327230) (← links)
• Clump formation in mouse pituitary-derived non-endocrine cell line Tpit/F1 promotes differentiation into growth-hormone-producing cells (Q38709453) (← links)
• Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways (Q39945226) (← links)
• Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. (Q39957511) (← links)
• Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (Q40505318) (← links)
• Somatostatin and somatostatin receptors: from basic concepts to clinical applications (Q43028510) (← links)
• New medical treatments in pituitary adenomas (Q46292544) (← links)
• Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report (Q47799841) (← links)
• Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. (Q48364648) (← links)
• International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature (Q57144951) (← links)
• In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 (Q61952374) (← links)